Investor Presentaiton
Q3FY24 financial highlights
Particulars
Q3 FY24 Q3 FY23
YOY
change
Q2 FY24 QoQ change
Revenue from operations
8,535
7,859
9%
9,101
-6%
Other income
293
172
70%
216
35%
Balance Sheet Highlights
Reported revenue
8,828
8,031
10%
9,317
-5%
Material costs
2,374
2,061
15%
2,672
-11%
As on 31st December 2023
Staff costs
2,405
2,192 10%
2,412
0%
Other direct costs
254
264
-4%
275
-8%
Shareholders' funds
40,284
Other expenses
1,063
876
21% 1,022
4%
Net Fixed assets
37,152
Foreign exchange (gain)/loss, net
124
156
-21%
179
-31%
Other net assets (1)
-842
EBITDA
2,608
2,482
5%
2,757
-5%
Net cash/(debt) (2)
3,974
EBITDA Margin
30%
31%
30%
Total Use of Funds
Depreciation and Finance Cost
1,189
1,083
10%
1,176
1%
40,284
PBT
1,419
1,399 1%
1,581
-10%
Tax
274
302
-9%
361
-24%
PAT before exceptional items
1,145
1,097
4%
1,220
-6%
PAT Margin
13%
14%
13%
PAT after exceptional items*
1,115
1,097
2%
1,167
-4%
*(Exceptional item (net of tax) in FY24 pertains to transaction costs relating to the acquisition of multi modal facility (Unit 3) of Stelis Biopharma Limited (SBL)
(1)Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less (Trade payables + Others current liabilities) at the end of the year
(2) Net cash/(Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year
Syngene
All figures in Rs. Mn unless otherwise specified
Putting Science to Work
28View entire presentation